LLY posted 48% revenue growth and controls 6 in 10 U.S. obesity prescriptions, while NVO cut 12,000 employees and saw gross margins fall to 78%.
Retatrutide hit Phase 3 endpoints with weight loss approaching bariatric surgery levels, with Lilly targeting a U.S. BLA submission in Q1 2027.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 results in early August, and the split screen was jarring.
Lilly delivered 48% revenue growth and raised guidance. Novo defended a shrinking U.S. business with price cuts, layoffs, and a fresh round of pipeline impairments. Same week, same category, opposite momentum.
#lilly #NYSE #same #NVIDIA
Retatrutide hit Phase 3 endpoints with weight loss approaching bariatric surgery levels, with Lilly targeting a U.S. BLA submission in Q1 2027.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 results in early August, and the split screen was jarring.
Lilly delivered 48% revenue growth and raised guidance. Novo defended a shrinking U.S. business with price cuts, layoffs, and a fresh round of pipeline impairments. Same week, same category, opposite momentum.
#lilly #NYSE #same #NVIDIA
21 days ago
